MediBiofarma
Medibiofarma is a clinical-stage Spanish biotech developing patented small-molecule therapies for fibrotic Crohn's disease (MBF-118), Huntington's disease (MBF-015), and solid-tumor immunotherapy (MBF-362), with a business model based on advancing assets through clinical proof-of-concept and out-licensing to large pharmaceutical partners.
- Company typePrivate
- Founded2016
- HeadquartersNoáin, Spain
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What MediBiofarma does
Medibiofarma is a clinical-stage Spanish biotechnology company founded in 2016 in Navarra, focused on discovering and developing new chemical entities (NCEs) for high-unmet-need diseases in fibrosis, neurodegeneration, and oncology. The company operates three wholly-owned, patented small-molecule programs: MBF-118, a covalent partial agonist of PPAR-γ for fibrotic Crohn's disease (Phase IIa completed August 2025); MBF-015, a brain-penetrant HDAC1/2 inhibitor for Huntington's disease (Phase IIa); and MBF-362, a selective EP4 receptor antagonist for solid-tumor immunotherapy (Phase Ib). Discovery and medicinal chemistry are performed in-house at a 200 sqm shared laboratory in Cordovilla with sister-company Palobiofarma, while in vivo pharmacology, toxicology, and IND-enabling studies are outsourced to CROs and academic centers. The company has no marketed products and no current product revenue; its business model is to advance compounds through clinical proof-of-concept and then out-license them to large pharmaceutical companies for late-stage development and commercialization. Capital is sourced from a mix of equity rounds led by Sodena (Government of Navarra) and Inveready, supplemented by non-dilutive grants from the European Commission (EIC, FEDER), CDTI, ENISA, the Ministry of Science and Innovation, and venture philanthropy awards from the Crohn's & Colitis Foundation. Strategic investors and partners include Asabys Partners (via the Oriva Therapeutics spin-off for women's health), and clinical operations run through Spanish hospital sites including CHUS, Hospital Sant Pau, and ICO Barcelona.
MediBiofarma firmographics
Firmographics- Name
- MediBiofarma
- Legal name
- MEDIBIOFARMA, S.L
- Website
- https://medibiofarma.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Medibiofarma is a clinical-stage Spanish biotech developing patented small-molecule therapies for fibrotic Crohn's disease (MBF-118), Huntington's disease (MBF-015), and solid-tumor immunotherapy (MBF-362), with a business model based on advancing assets through clinical proof-of-concept and out-licensing to large pharmaceutical partners.
- Ownership category
- akta.pro rank
MediBiofarma industry classification
Industry- Product category
- Clinical-stage biopharmaceutical drug development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where MediBiofarma is headquartered
LocationHeadquarters
- HQ city
- Noáin
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
MediBiofarma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Out-licensing / Big Pharma licensing agreements: Pre-commercial biotech company with no current revenue. Primary value creation strategy is to advance clinical assets through proof-of-concept and out-license to large pharmaceutical companies for further development and commercialization. Licensing agreements represent the intended primary revenue mechanism.
- Non-dilutive funding / Grants: Company receives public grant funding from Government of Navarra, European Commission (EIC, FEDER), CDTI, ENISA, Ministry of Science, and Crohn's & Colitis Foundation. This non-dilutive capital supports R&D operations.
- Spinoff asset monetization: Assets have been spun off to create value: ORV-499 (uterine fibroids program) was contributed to Oriva Therapeutics in exchange for equity/stake in the new company, representing a non-traditional revenue mechanism.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels4 records
MediBiofarma product offering
Product offeringCore offering
MediBiofarma discovers and develops proprietary new chemical entities (small molecules) for high-unmet-need diseases. Its portfolio comprises three clinical-stage drug candidates: MBF-118 (covalent PPAR-γ partial agonist for fibrotic Crohn's disease), MBF-015 (HDAC1/2 inhibitor for Huntington's disease and other synaptopathies), and MBF-362 (EP4 antagonist for solid tumor immunotherapy). The company runs in-house medicinal chemistry, in vitro pharmacology, IP, clinical trials, and business development, and outsources in vivo pharmacology, toxicology, and IND-enabling work to CROs.
Product overview
MediBiofarma is a clinical-stage biotechnology company developing a portfolio of small molecule drug candidates targeting diseases with high unmet medical need. The company operates three clinical-stage programs: MBF-118 (PPARγ partial agonist for fibrotic Crohn's disease), MBF-362 (EP4 antagonist for cancer immunotherapy), and MBF-015 (HDAC1/2 inhibitor for neurodegenerative diseases). The company focuses on drug discovery, medicinal chemistry, and clinical development, outsourcing non-core activities like in vivo pharmacology and toxicology to CROs.
Differentiator
Problem solved
Functional benefit
Products and services
- MBF-118 Potent and selective covalent partial agonist of the PPAR-γ nuclear receptor in development for fibrosis in Crohn's disease. Demonstrates anti-fibrotic and anti-inflammatory properties with GI-enriched pharmacokinetics in humans and limited systemic exposure. Granted US and EU patents, wholly owned.
- MBF-015 Selective CoREST/HDAC1/2 inhibitor for synaptopathies and neurodegenerative diseases. Crosses the blood-brain barrier, demonstrates induction of synaptic regrowth in animal models, and has a broad therapeutic window with no genotoxic potential. Granted US and EU patents, wholly owned.
- MBF-362 Potent and selective antagonist of the prostaglandin EP4 receptor designed for cancer immunotherapy. Demonstrates efficacy in solid tumor models and synergy with anti-PD-L1 antibodies. Currently in Phase Ib dose escalation. Patent wholly owned.
Quantifiable outcome
- MBF-118 Phase IIa completed August 2025: excellent safety and tolerability demonstrated in Crohn's disease patients, with preliminary efficacy signals and qualitative improvements in stricture characteristics in some patients.
- +4 more outcomes
Companies that use MediBiofarma
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles1 record
MediBiofarma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
MediBiofarma partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered minor and core.
- Oriva TherapeuticsminorWomen's health spin-off company seeded by Asabys Sabadell Asabys II. Medibiofarma contributed an advanced asset (ORV-499, uterine fibroids program) to Oriva. Julio Castro co-founded both companies. Positions Medibiofarma as a strategic contributor of clinical assets to new entity.
- CROs, Research Centers, and UniversitiescoreFor full characterization and nomination of development candidates, Medibiofarma outsources in vivo pharmacology, toxicology, and IND-enabling studies to contract research organizations (CROs). Also partners with research centers and universities for specialized research capabilities.
- Hospital complex of the University of Santiago de Compostela (CHUS)coreClinical trial site for Phase IIa trial of MBF-118 in Crohn's disease patients. Under supervision of Dr. Manuel Barreiro, Associate Professor of Digestive Medicine and President of GETECCU (Spanish Crohn's and Colitis workgroup).
- Hospital de la Santa Creu i Sant Pau, BarcelonacoreClinical trial site for Phase IIa trial of MBF-015 in Huntington's disease patients. Under supervision of Dr. Jaime Kulisevsky, head of Movement Disorders Unit and Director of CDINC. Dr. Kulisevsky is a member of the executive committee of the European Huntington's Disease Network (EHDN).
- Catalan Institute of Oncology (ICO), BarcelonacoreClinical trial site for Phase I trial of MBF-362 in cancer patients with solid tumours. Phase Ib dose escalation trial determining safety, tolerability, pharmacokinetic profile, DLT, MTD, and RP2D.
- OncostellaecoreGalician clinical-stage biopharma company. Medibiofarma and Oncostellae share common promoter team (Julio Castro). Both companies collaborated on the NAIARA consortium. Medibiofarma contributed an asset (ORV-499) to the Oriva Therapeutics spinout alongside Oncostellae's endometriosis program.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
MediBiofarma competitors and assessment
Company assessmentDirect peers
- Genfit SA: French clinical-stage biotech developing PPAR-targeted small molecules (elafibranor, PPAR-α/δ agonist) for fibrotic and metabolic liver diseases. Most direct mechanism peer to MediBiofarma's MBF-118 covalent PPAR-γ partial agonist and similar preclinical-to-Phase II translational stage with Big Pharma out-licensing strategy.
- Pliant Therapeutics: US clinical-stage small molecule biotech advancing integrin-based therapies for fibrosis (IPF, PSC). Closely comparable in therapeutic focus (fibrosis), platform modality (small molecules) and clinical-stage inflection-driven licensing business model; cross-Atlantic counterpart in fibrosis drug development.
- Prilenia Therapeutics: Clinical-stage biotech developing pridopidine (sigma-1 receptor agonist) for Huntington's disease and ALS. Directly comparable small-molecule, CNS-focused clinical-stage approach to MediBiofarma's MBF-015, and similar in pursuing licensing or strategic transaction exits following Phase II/III readouts.
- Wave Life Sciences: Clinical-stage biotech with WVE-003 (allele-selective antisense oligonucleotide) in Huntington's disease Phase 1b/2a. Direct indication peer for MediBiofarma's MBF-015 program, validating Huntington's as a viable clinical-stage licensing target though using a different modality (ASO vs small molecule).
- Minoryx Therapeutics: Spanish/Andorran clinical-stage biotech developing small-molecule therapies for CNS orphan diseases (lead asset leriglitazone, a PPAR-γ agonist for X-ALD). Strong peer for MediBiofarma on geographic, modality, mechanistic (PPAR family) and therapeutic-area overlap; MediBiofarma's CSO was previously Director of Drug Discovery at Minoryx.
- Redx Pharma: UK-listed clinical-stage biotech developing targeted small molecules in fibrosis and oncology. Comparable to MediBiofarma as a Europe-based clinical-stage small molecule platform pursuing licensing deals in fibrosis and immuno-oncology.
- Liminal Biosciences: Canada-based clinical-stage biotech developing first-in-class small molecule inhibitors targeting the GPR40 receptor for inflammatory and fibrotic diseases. Comparable late-preclinical/early-clinical-stage fibrosis small molecule biotech with out-licensing strategy.
- Vivace Therapeutics: US clinical-stage small molecule biotech focused on precision oncology, including Hippo-YAP/TEAD pathway inhibitors and immuno-oncology combinations. Comparable scale, modality and out-licensing-oriented model to MediBiofarma's MBF-362 EP4 antagonist program targeting tumor immune evasion.
Broad incumbents
- Galapagos NV: Belgian clinical-stage and specialty pharma company with deep gastroenterology/inflammation pipeline (filgotinib JAK1 in Crohn's) and a broader small-molecule discovery engine. Broader incumbent peer whose IBD franchise validates market demand for MediBiofarma's MBF-118 in fibrotic Crohn's while competing for BD dollars.
- Karuna Therapeutics: CNS-focused clinical-stage biotech (xanomeline-trospium) acquired by Bristol-Myers Squibb for $14B. Comparable CNS clinical-stage innovation model and validates strong BD appetite for differentiated small-molecule CNS assets with Phase II efficacy — directly relevant precedent for MBF-015 in Huntington's.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
MediBiofarma social profiles
Digital presenceMediBiofarma compliance and trust
Trust signalCompliance1 record
MediBiofarma financial estimates
Financial estimateRevenue estimate
Valuation estimate
MediBiofarma leadership team
Management profileNumber of profiles
Profiles5 records
MediBiofarma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
MediBiofarma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about MediBiofarma
What does MediBiofarma do?
MediBiofarma discovers and develops proprietary new chemical entities (small molecules) for high-unmet-need diseases. Its portfolio comprises three clinical-stage drug candidates: MBF-118 (covalent PPAR-γ partial agonist for fibrotic Crohn's disease), MBF-015 (HDAC1/2 inhibitor for Huntington's disease and other synaptopathies), and MBF-362 (EP4 antagonist for solid tumor immunotherapy). The company runs in-house medicinal chemistry, in vitro pharmacology, IP, clinical trials, and business development, and outsources in vivo pharmacology, toxicology, and IND-enabling work to CROs.
Is MediBiofarma a public or private company?
MediBiofarma is a private company. It is classified as venture growth investor backed and is currently operating.
When was MediBiofarma founded?
MediBiofarma was founded in 2016. It employs 1 to 10 people.
Where is MediBiofarma based?
MediBiofarma is headquartered in Noáin, Spain, in the Europe region.
How does MediBiofarma make money?
Three revenue lines are on record. Out-licensing / Big Pharma licensing agreements are the primary driver. The others are non-dilutive funding / Grants and spinoff asset monetization.
Who are MediBiofarma's main competitors?
Direct peers on record are Genfit SA, Pliant Therapeutics, Prilenia Therapeutics, Wave Life Sciences, Minoryx Therapeutics, Redx Pharma, Liminal Biosciences and Vivace Therapeutics. Broad incumbents are Galapagos NV and Karuna Therapeutics.
Does MediBiofarma have an API?
No public API is recorded for MediBiofarma.
What industry is MediBiofarma in?
MediBiofarma's product category is Clinical-stage biopharmaceutical drug development. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 541714.